Contingent negative variation: a biomarker of abnormal attention in functional movement disorders by Teodoro, T et al.
Contingent negative variation: a biomarker of abnormal attention in
functional movement disorders
T. Teodoroa,b,c,d , A. Korekia,e, A. M. Meppelinkf, S. Littleg, G. Nielsena, A. Macerolloh ,
J. J. Ferreirad,i , I. Pareesj,k, A. Langl,m and M. J. Edwardsa,b,c
aNeurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George’s,University of London, London; bSt
George’s University Hospitals NHS Foundation Trust, London; cAshford and St Peter’s Hospital NHS Foundation Trust, Chertsey, UK;
dInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; eDepartment of Neuropsychiatry,
National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba, Japan; fStichting Epilepsie Instellingen Nederland, Zwolle,
The Netherlands; gDepartment of Clinical and Movement Neurosciences, UCL Institute of Neurology, Queen Square, London, UK; hThe
Walton Centre, Liverpool, UK; iCNS-Campus Neurologico Senior, Torres Vedras, Portugal; jHospital Ruber Internacional, Madrid;
kNeurology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain; lEdmond J. Safra Program in Parkinson’s Disease,
Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto,
Toronto, Ontario; and mKrembil Brain Institute, Toronto, Ontario, Canada
Keywords:
biomarkers, functional
neurological disorders,
functional movement
disorders, psychogenic
disorders
Received 5 November 2019
Accepted 22 February 2020
European Journal of
Neurology 2020, 27: 985–994
doi:10.1111/ene.14189
Background and purpose: Contingent negative variation (CNV) is a negative
cortical wave that precedes a pre-cued imperative stimulus requiring a quick
motor response. It has been related to motor preparation and anticipatory
attention. The aim was to ascertain whether the clinical improvement of func-
tional movement disorders after physiotherapy would be associated with faster
reaction times and modulation of CNV.
Methods: Motor performance and CNV were analysed during a pre-cued
choice reaction time task with varying cue validity. Twenty-one patients with
functional movement disorders and 13 healthy controls at baseline were com-
pared. Patients then underwent physiotherapy. At follow-up after physiother-
apy, patients were categorized as clinically improved (responders) or not
improved (non-responders) and retested.
Results: At baseline, patients did not generate CNV, contrary to controls
[mean amplitude (µV) at the end of preparation to move: patients 0.47 (95%
CI 1.94, 1.00) versus controls 2.59 (95% CI 4.46, 0.72)]. Responders
performed faster after physiotherapy [mean natural logarithm (ln) reaction
time (RT) (ms): follow-up 6.112 (95% CI 5.923, 6.301) versus baseline 6.206
(95% CI 6.019, 6.394), P = 0.010], contrary to non-responders. Simultane-
ously, responders showed a recovery of CNV after physiotherapy [follow-up
1.95 (95% CI 3.49, 0.41) versus baseline 0.19 (95% CI 1.73, 1.35),
P < 0.001], contrary to non-responders [follow-up 0.32 (95% CI 1.79,
1.14) versus baseline 0.72 (95% CI 2.19, 0.75), P = 0.381].
Conclusions: Clinical improvement of functional movement disorders after
physiotherapy was associated with faster reaction times and normalization of
CNV, which was absent at baseline. These findings suggest that CNV may
constitute a useful neurophysiological biomarker related to abnormal attention
in functional movement disorders.
Introduction
One of the most characteristic clinical features of
functional movement disorders (FMDs) is their alter-
ation with attention: when attention is focused onto
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movement, movement is impaired; but with distrac-
tion, movement typically normalizes [1]. This phe-
nomenon of abnormal explicit control of movement
and normal implicit control underlies commonly used
clinical and electrophysiological diagnostic tests of
FMDs such as Hoover’s sign and entrainment and
distractibility tests in functional tremor [2]. Atten-
tional focus towards the mechanics of moving (i.e.
monitoring the current state of the limb to be moved)
forms a central feature of neurobiological models of
FMD, whilst retraining attentional focus is a key part
of specific physiotherapy-based treatment programmes
[1,3-5]
There is some evidence of a pathophysiological role
for explicitly directed attention in FMD [1,6]. There-
fore, experimental techniques that directly probe
explicitly directed attention could help to identify
potential biomarkers for FMDs [6]. A useful biomar-
ker would be abnormal in people with FMD when
they were symptomatic and would normalize if
improvement of symptoms occurred.
The usefulness of a simple pre-cued reaction time
(RT) task, based on the classic Posner paradigm, as
a diagnostic biomarker for FMD was previously
explored [1,6]. In this paradigm, a pre-cue predicts
with varying probability which movement will be
required (a button press with the right or left hand)
following an upcoming ‘go’ cue. In an initial beha-
vioural study, it was shown that people with FMD,
in contrast to healthy controls, did not improve
their RT in response to a pre-cue that reliably pre-
dicted the type of movement they were required to
make [1]. In a subsequent study, this behavioural
effect was replicated and it was shown that the nor-
mal desynchronization of beta power that can be
detected by electroencephalography (EEG) prior to
cued movement was not present in people with
FMD performing this task [6]. A non-significant
trend for recovery of this beta desynchronization
was found in people with FMD who had improved
clinically following specific physiotherapy treatment
[6]. This suggested that excessive synchronization of
brain activity on the beta band could constitute a
biomarker for abnormal movement preparation in
FMD [6].
In this study, the utility of a different potential bio-
marker was explored: the contingent negative varia-
tion (CNV). CNV is a slow negative cortical wave
that develops following a pre-cue which signals that,
within a few seconds, an imperative stimulus will
arrive, requiring a quick motor response [7,8]. CNV is
regarded as an ‘expectancy wave’, reflecting anticipa-
tory attention and motor preparation to react to the
forthcoming cue [8,9].
In people with FMD, it was predicted that excessive
attention onto the current state of the limb to be moved
and away from the movement’s goal would be associ-
ated with an insufficient deployment of anticipatory
attention and abnormal motor preparation. This would
translate into slower RTs to the imperative cues (thus
replicating the findings of previous research) [1] and a
reduction in CNV amplitudes. In line with our expecta-
tions, a previous study of six patients with functional
weakness found a reduction in CNV amplitude which
was not evident in controls feigning weakness [10], and
a pre-movement potential before self-paced voluntary
movement has been reported to be absent in people
with functional jerks [11].
Therefore, in this study, it was hypothesized that (i)
CNV amplitude would be reduced at baseline in com-
parison with healthy controls; (ii) clinical improve-
ment after physiotherapy would be associated with
faster RT and recovery of CNV.
Methods
Participants, experimental task and EEG recording
A case–control study was performed comparing
patients with FMD and healthy volunteers. Patients
with FMD were recruited from a pool of patients being
enrolled in a randomized feasibility study comparing
specialized with standard physiotherapy for FMD [5].
A detailed description of the specialized physiotherapy
programme is given in Appendix S1. These subjects
were ≥ 18 years old and had a clinically established
diagnosis of FMD according to the Fahn–Williams cri-
teria [12]. All patients attended a consultation with the
study neurologist (MJE). Additional inclusion criteria
were a symptom duration of at least 6 months, func-
tional motor symptoms causing significant disability, a
completed diagnostic investigation and acceptance of
the diagnosis of FMD. Relevant exclusion criteria were
the presence of pain or fatigue as the primary cause of
disability, prominent dissociative seizures, clinically sig-
nificant depression or anxiety and a high level of dis-
ability preventing participation in an outpatient
environment [5]. FMD participants were tested before
starting physiotherapy (baseline) and at least 2 weeks
after completing treatment (follow-up) (Table 1).
Matched healthy controls were assessed only once [6].
Phenomenology at baseline was characterized on the
basis of a video rating by three neurologists, as
described elsewhere (Table 1) [13].
Assessment of clinical improvement after physio-
therapy was based on Clinical Global Impression
(CGI), the Physical Function domain of the Short-
Form Health Survey (SF-36) (version 1) and the
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Simplified Functional Movement Disorders Rating
Scale (S-FMDRS) [5,13,14]. Patients with FMD were
dichotomized as responders or non-responders to
physiotherapy, based on their self-rated CGI [5].
Responders self-rated themselves as improved or
much improved after physiotherapy. Non-responders
self-rated as unchanged, worse or much worse. Our
study was nested within a randomized feasibility trial
that used the same criteria for collapsing the CGI [5].
The Physical Function domain of the SF-36 question-
naire focuses on motor function, inquiring about limi-
tations on 10 mobility activities [14]. Finally, the S-
FMDRS is a simplified version of the Functional
Movement Disorders Rating Scale and has shown
good inter-rater reliability and sensitivity to change
[13]. The raters of S-FMDRS were blinded for time-
point of assessment (before versus after treatment), as
reported elsewhere [13].
Our behavioural experiment consisted of a Posner-
type pre-cued choice RT task with varying cue validity
[1,6,15], including (i) a highly predictable condition,
where preparation cues accurately predicted go cues in
95% of the trials (95% congruence); (ii) an unpre-
dictable condition, where preparation cues accurately
predicted go cues in only 50% of the trials (50% con-
gruence). Participants were instructed to press the key
corresponding to the go cue as quickly as possible (ei-
ther the left Ctrl key with left index finger or right Ctrl
key with right index finger). A flowchart with the trial
structure was included in a previous publication [6].
Response time in milliseconds (ms) was calculated
for each trial. Trials where the preparation cue accu-
rately predicted the go cue (congruent) were separated
from those where the prediction was incorrect (incon-
gruent). RTs were separately averaged across trials for
congruent and incongruent trials in each of the two
conditions.
Continuous EEG was recorded using a 32-channel
ANT-EEG (ANT Neuro, Hengelo, Netherlands)
system conforming to the 5% electrode system. Our
reference was an average of all electrodes. Trials with
prominent artefacts and trials where participants
pressed the wrong key or did not press any key were
excluded.
A more detailed description of the participants,
experimental task and EEG recording can be found
elsewhere [6].
Pre-processing
Statistical Parametric Mapping (12b, The Wellcome
Centre for Human Neuroimaging, UCL Queen Square
Institute of Neurology, London, UK) and MATLAB
(MathWorks, Natick, MA, USA) were used for data
processing. Data were downsampled from 2048 to
250 Hz and epoched to frames from 1 to +4 s relative
to the onset of the preparation cue. The interval preced-
ing the preparation cue was selected as baseline and
baseline-corrected the epoched frames. Finally, data
were averaged over trials for each participant and
extracted data from the Cz electrode (amplitude, µV),
which is considered to record CNV with greatest ampli-
tude [16]. The midline location of Cz also facilitated
combining data from right and left key presses. This
maximized the statistical power to compare subgroups
of patients with FMD who improved and did not
improve after physiotherapy (see below).
Pre-processing resulted in four datasets of Cz ampli-
tude as a function of time: (a) 95% trial, right key
press (right index finger); (b) 95% trial, left press (left
index finger); (c) 50% trial, right press; (d) 50% trial,
left press.
Table 1 Functional movement disorder patients at baseline versus
follow-up: demographics and response to treatment
Groups FMD responders
FMD
non-responders
N total 10 11
Sex (males/females) 2/8 2/9a,**
Age, years (median, IQR) 43 (30–45) 41 (36–53)a,**
Phenomenologyb
Gait impairment 7 7
Motor slowness 0 1
Incoordination 1 1
Upper limb tremor 2 4
Head tremor 0 2
Trunk tremor 1 1
Axial myoclonus 1 1
Functional dystonia 1 1
Upper limb
involvement (any)
3 5
Bilateral involvement 6 7
Right-sided involvement 0 3
Left-sided involvement 3 1
Number of patients
who received
specialized physiotherapy
8/10 1/11a,*
SF-36 (median, IQR)
Baseline 30 (20–50) 25 (10–30)
Follow-up at 6 months 60 (35–80)c,* 15 (5–40)c,**
S-FMDRS (median, IQR)
Baseline 15 (9–21) 14 (12–18)
Follow-up at 6 months 5 (2–13)c,* 24 (16–33)c,**
SF-36 baseline versus follow-up (Wilcoxon sign-rank test): for
responders P = 0.021; for non-responders P = 0.433. S-FMDRS
baseline versus follow-up (Wilcoxon sign-rank test): for responders
P = 0.044; for non-responders P = 0.074. FMD, functional move-
ment disorder; IQR, interquartile range; SF-36, Short-Form Health
Survey; S-FMDRS, Simplified Functional Movement Disorders Rat-
ing Scale. aResponders versus non-responders. bBased on baseline
video rating by three neurologists [13]. cBaseline versus follow-up.
*P < 0.05; **P ≥ 0.05.
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Statistical analysis
Statistical analysis was performed using Stata (version
13.1, College Station, TX, USA,). Continuous variables
were expressed as mean (and standard deviation) if nor-
mally distributed or median (and interquartile range) if
not normally distributed. Categorical variables were
expressed as frequencies and proportions. The normality
assumption was assessed by visually inspecting the distri-
bution of the continuous variable and confirmed by Kol-
mogorov–Smirnov testing.
Reaction times (RTs) were non-normally distributed
and were therefore transformed into their natural loga-
rithms (ln), in order to fulfil the normality assumption and
thus be able to fit a multilevel mixed effect linear model.
Participants could pre-plan the forthcoming key
press in the interval between the appearance of prepa-
ration and go cues (interval duration 1950 ms). CNV
amplitude (µV) at the moment of maximum prepara-
tion was analysed by restricting our analysis to the
last 12 ms preceding the go cue (averaging data from
three data points).
Our outcome measures were RT (ms) and CNV
amplitude (µV) at the end of preparation to move.
Mixed effects multilevel linear modelling allowed the
dependence in the data caused by repeated measure-
ments within-subjects to be taken into account. The
following models were fitted.
• A baseline comparison was made of patients with
FMD and healthy controls.
• Behavioural results (RTs) for baseline compar-
ison were presented in our previous paper focus-
ing on beta oscillations (see summary below) [6].
• For CNV amplitude, the effects of group, pre-
dictability and hand, their interactions and an
individual level random effect were included.
• A comparison was carried out of FMD respon-
ders and non-responders to physiotherapy, before
and after this intervention.
• For RT, our analysis was restricted to trials with
congruent preparation and go cues, as those were
the ones thought to reflect motor preparation. A
model was fitted including the effects of time-
point (baseline versus follow-up), response (re-
sponder versus non-responder) and predictability
(95% vs. 50%), their respective interactions and
an individual level random effects factor.
• For CNV amplitude, the effects of group, pre-
dictability and hand, their interactions and an
individual level random effect were included.
Finally, the relationship between changes in CNV and
changes in RT at follow-up was investigated. The grand
average of end-of-preparation CNV (µV) and RT (ms)
at baseline and at follow-up was calculated, for each
participant. The baseline averages were then subtracted
from the follow-up averages for both parameters. It was
planned to regress the average change of RT against the
average change of end-of-preparation CNV.
Statistical significance was predefined as P < 0.05.
Ethics
This study was approved by the local ethics commit-
tee. Participants gave their informed written consent
to take part in the studies.
Results
Clinical and demographic characteristics
Twenty-one patients with FMD and 13 healthy con-
trols were recruited and a baseline assessment was
performed. Nine patients with FMD were randomized
to undergo specialized physiotherapy and another 12
to receive standard physiotherapy. Groups at baseline
were well matched for age, sex and proportion of left-
handed participants (reported elsewhere [6]).
Patients with FMD were evaluated after a mean per-
iod of 4.7 weeks (SD 1.7) after treatment. Ten patients
with FMD were classified as responders and 11 as non-
responders, in accordance with their self-rated CGI.
FMD responders, contrary to non-responders, showed
an increase in SF-36 and a decrease in S-FMDRS at
follow-up (Table 1). The age and sex proportions were
similar in both groups. Eight out of 10 responders and
one out of 11 non-responders had been randomized to
receive specialized physiotherapy, whilst the others
underwent standard physiotherapy [5].
Functional movement disorder patients at baseline
versus healthy controls
Behavioural results
For RT, it has been previously reported elsewhere [6]
that healthy controls performed faster in trials with pre-
dictive pre-cues compared with trials with non-predictive
pre-cues [mean ln(RT) predictive pre-cues 6.104 (95%
CI 5.947, 6.261) versus non-predictive pre-cues 6.162
(95% CI 6.006, 6.319), P = 0.032] (Fig. 1). In contrast, in
patients with FMD, RTs were similar in predictive and
non-predictive pre-cues [mean ln(RT) predictive pre-cues
6.287 (95% CI 6.166, 6.408) versus non-predictive pre-
cues 6.314 (95% CI 6.194, 6.435), P = 0.206].
End-of-preparation CNV
A significant effect for group (P = 0.050) was found
but not for predictability (P = 0.484), hand (P =
0.496) or the interactions group 9 predictability (P =
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0.459), group 9 hand (P = 0.245), predictability 9
hand (P = 0.923) and group 9 predictability 9 hand
(P = 0.361) (Fig. 2, Table S4).
After eliminating all non-significant factors from
our model, the P value for the pairwise comparison
between FMD and healthy controls was 0.081 [mean
FMD 0.47 (95% CI 1.94, 1.00) versus healthy con-
trols 2.59 (95% CI 4.46, 0.72)]. Importantly,
patients with FMD failed to generate the negative
wave that defines CNV (P = 0.532 for rejecting the
null hypothesis of CNV amplitude being zero), con-
trary to healthy controls (P = 0.007).
Functional movement disorder patients at follow-up
versus baseline
Behavioural results
In our predefined model of normalized RT, the only
significant effect was for the interaction response 9
time-point (P = 0.012). None of the other terms was
significant, including response (P = 0.184), time-point
(P = 0.140), predictability (P = 0.755), response 9 pre-
dictability (P = 0.691), time-point 9 predictability (P
= 0.466) and response 9 time-point 9 predictability
(P = 0.498). Responders at follow-up were unable to
take advantage of predictive conditions (95% congru-
ence) to perform faster, compared with non-predictive
conditions (50% congruence) (P = 0.643 for the corre-
sponding pairwise comparison). This specific finding is
similar to what has been described elsewhere for
patients with FMD at baseline [6].
In order to dissect the significant interaction
between response 9 time-point, a pairwise compar-
ison analysis was then performed in a model only
including response, time-point and their interaction.
In accordance with our predictions, responders per-
formed faster at follow-up than at baseline [mean ln
(RT) at follow-up 6.112 (95% CI 5.923, 6.301) versus
Figure 1 Natural logarithm of reaction time per group, predictability and cue congruence. 50%, 50% congruence blocks (including
congruent cues in 50% trials); 95%, 95% congruence blocks; C, trials with congruent cues; I, trials with incongruent cues. [Colour
figure can be viewed at wileyonlinelibrary.com]
Figure 2 End-of-preparation CNV: FMD patients at baseline versus healthy controls. [Colour figure can be viewed at wileyonlinelibrary.com]
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baseline 6.206 (95% CI 6.019, 6.394), P = 0.010]
whilst non-responders’ performance was similar [mean
ln(RT) at follow-up 6.444 (95% CI 6.265, 6.623) ver-
sus baseline 6.401 (95% CI 6.222, 6.579), P = 0.185].
See Table S1 for non-normalized RT, Fig. 1 and
Table S2 for the corresponding natural logarithms
and Table S3 for the accuracy results.
End-of-preparation CNV
In our predefined model, the effects of response (P =
0.626) and time-point (P = 0.381) were non-significant
but their interaction was significant (P = 0.001) (Fig. 3,
Table S4). In order to clarify this interaction, a pairwise
comparison analysis was performed. After physiother-
apy, the power at the end of preparation to move
became more negative in responders [mean, follow-up
1.95 (95% CI 3.49, 0.41) versus baseline 0.19
(95% CI 1.73, 1.35), P < 0.001] but not in non-re-
sponders [mean, follow-up 0.32 (95% CI 1.79, 1.14)
versus baseline 0.72 (95% CI 2.19, 0.75), P = 0.381].
Notably, only responders at follow-up generated a neg-
ative wave at the end of preparation to move [mean
1.95 (95% CI 3.49, 0.41), P = 0.013].
Relationship between changes in RT and in CNV at fol-
low-up. In responders, RT became 41 ms (SD 31)
faster at follow-up, whilst the end-of-preparation
CNV became 1.97 (SD 2.12) more negative at fol-
low-up. In contrast, in non-responders, RT became
12 ms (SD 159) slower and the end-of-preparation
CNV 0.40 (SD 4.56) more positive at follow-up.
In the linear regression of changes in RT against
changes in end-of-preparation CNV, the RT became
19 ms faster for each 1 µV increase in CNV nega-
tivity (P = 0.004) (Fig. 4).
Discussion
Here it is reported that CNV is abnormal in people
with FMD and that clinical improvement that
occurred following treatment is associated with its
normalization. In contrast, people with FMD who did
not experience clinical improvement with treatment
continued to demonstrate abnormal CNV at follow-
up assessment.
Suppression of CNV and abnormal motor preparation
in FMD
It has been previously observed that people with
FMD are unable to take advantage of highly pre-
dictable conditions to prepare for the forthcoming
movement and improve performance (i.e. generate fas-
ter RTs) [1,6]. This finding is in accordance with their
difficulty in performing movements in an explicit con-
text (e.g. to command during a physical examination),
but retained ability for normal movement to occur
when happening in an automatic or implicit manner.
It has been previously proposed that this reflects a
misdirection of attention towards the mechanics of a
movement and away from its goal, in line with neuro-
biological accounts of FMD [1,17]. It has recently
been demonstrated that this behavioural phenomenon
is associated with persistent beta synchronization dur-
ing motor preparation, which showed a non-
Figure 3 End-of-preparation CNV: FMD responders and non-responders at baseline versus follow-up. [Colour figure can be viewed at
wileyonlinelibrary.com]
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significant trend towards recovery of normal beta sup-
pression prior to movement, following clinical
improvement after treatment [6].
Contingent negative variation is related to anticipa-
tory attention and motor preparation [8,9]. Therefore,
the suppression of CNV observed in our patients at
baseline probably reflects abnormalities in motor
preparation and attention, in keeping with the mecha-
nism hypothesized in the Introduction [1,17].
Only one previous study reported suppression of
CNV in FMD, in a group of six patients with func-
tional weakness. Suppression of CNV was not
observed in a group of 24 participants feigning paraly-
sis, despite similar motor performances, or in a group
of 12 healthy subjects [10].
In addition, FMD patients were highly accurate in
their performance (95.3% vs. 98.8% in controls)
which it is believed is evidence against feigning as an
explanation for their lack of CNV (Table S3).
Functional improvement and recovery of CNV
It was found that clinical improvement in responders
was associated not only with faster RT but also with
a recovery of CNV after treatment. The same was not
observed in non-responders, ruling out confounding
by a simple retesting effect. Physiotherapy for FMD is
based on movement retraining with the aim of restor-
ing normal movement by redirecting the focus of
motor attention towards the movement goal and away
from movement mechanics [4,5]. CNV recovery at fol-
low-up could therefore plausibly reflect a successful
retraining of movement, with a refocusing of motor
attention towards the movement goal. To our knowl-
edge, only one previous study has reported change in
a neurobiological marker of nervous system dysfunc-
tion following successful treatment [18]. Vuilleumier
et al. observed a decrease in thalamic and basal gan-
glia single-photon emission computed tomography
activation in response to contralateral limb vibration
in seven patients with unilateral functional motor
symptoms, which normalized after symptom improve-
ment at follow-up [18].
Cues to interpret previous findings on
Bereitschaftspotentials
Our results may help explain rather unusual results
from assessment of Bereitschaftspotentials (BPs, pre-
movement potentials recorded prior to self-paced
movement) in people with functional myoclonus [11].
In these patients, functional jerks are associated with
the expected presence of a BP, but, intriguingly, vol-
untarily mimicked jerks are not associated with a BP.
Taken together, these results point to a general prob-
lem in voluntary movement (self-paced or externally
paced), which is reflected in abnormalities of cortical
potentials associated with movement preparation.
Relevance of symptom distribution
A crucial facet of the data presented here is that CNV
relating to movement preparation for right or left arm
movement was recorded, but many of the patients did
Figure 4 Relationship between changes in RT and in CNV at follow-up. [Colour figure can be viewed at wileyonlinelibrary.com]
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not have symptoms in their arms or, in some patients,
only one arm was affected. Despite this, there was no
systematic difference in our findings between those
with or without clinical involvement of the upper
limbs. This fits with our clinical experience that it is
very common for functional motor signs to be trig-
gered through the act of physical examination, even in
patients who do not complain of specific symptoms in
the limb being examined. Indeed this phenomenon is
commonly seen in people with non-motor functional
symptoms, e.g. chronic pain, functional sensory loss,
chronic fatigue. In such patients, examination of
power commonly reveals give-way patterns of weak-
ness, a positive Hoover’s sign, or flurries of jerks and
tremors. This is in accordance with the common co-
occurrence of functional symptoms in different
domains (motor, exteroception, interoception) and
with neurobiological accounts of functional neurologi-
cal disorders which make no separation between the
mechanism of functional symptoms that occur in dif-
ferent domains. This is important information for the
potential use of CNV as a neurophysiological diag-
nostic biomarker, as it does not require people to
have symptoms in the limbs being studied, and it also
may be of use in those with non-motor functional
symptoms. This requires further study, but could indi-
cate a more general utility of CNV as a biomarker
related to abnormal attention in functional neurologi-
cal disorder.
Limitations
There are several limitations to our study. It was
decided to use data from the lead Cz because this is
previously reported to provide CNV with the largest
amplitude. Our main interest here was studying FMD
responders and non-responders, which restricted our
sample size. Therefore, it was decided to prioritize
testing for differences in CNV amplitudes over investi-
gating CNV lateralization, which is obviously not pos-
sible with Cz.
Patients were dichotomized into responders and
non-responders based on one self-rated outcome mea-
sure (CGI). However, changes in SF-36 (self-reported
quality of life measure) and S-FMDRS (video rating
blinded for time-point [13]) after treatment also sup-
ported our criteria for collapsing groups over CGI
(Table S1–S4). It is acknowledged that abnormalities
in CNV (using different paradigms from ours) have
been reported in other disorders. For example, CNV
attenuation has been described in Parkinson’s disease
[19], schizophrenia [20] and attention-deficit hyperac-
tivity disorder [21], and an enhancement was observed
in Gilles de la Tourette syndrome [22]. It would be
useful for future studies to include movement disorder
disease control groups to understand the nature of the
overlap between CNV abnormalities in people with
FMD and those with other disorders.
Experiments with long intervals between prepara-
tion and go cues have described an early and late
component of CNV. Notwithstanding significant con-
troversy, late CNV was proposed to be more closely
related with the BP. Although the rules for decompos-
ing CNV into its early and late components are not
‘set in stone’, foreperiods of at least 3 s duration are
often used. Therefore, it is considered that our inter-
val was too short to allow a precise separation of
these components.
Responders’ RTs in congruent trials overall became
faster at follow-up, contrary to what was observed in
non-responders. However, there was a persistence of
some behavioural abnormalities, with patients with
FMD remaining unable to take advantage from pre-
dictive pre-cues to perform even faster (contrary to
healthy controls, as reported elsewhere [6]).
Contingent negative variation abnormalities were
previously described in other movement disorders,
including Parkinson’s disease [19], writer’s cramp [23],
cervical dystonia [24] and Huntington disease [25].
Therefore, abnormal CNV is not specific to patients
with FMD, which limits its utility for the differential
diagnosis with other movement disorders.
In conclusion, a recovery of CNV in the context of
a clinical and behavioural improvement after physio-
therapy is described. These findings suggest that CNV
is a potential candidate biomarker for treatment
response in FMD, and indeed may have utility outside
the setting of those with FMDs and be useful in func-
tional neurological disorder in general.
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